5 chapters across the catalog
A breakdown of vaccine "versions" describes whole-virus vaccines as 1.0, protein-based vaccines as 2.0, and mRNA as 3.0 technology. The comparison of biology to software technology is criticized as a marketing tactic. Additionally, a "summer surge" of COVID-19 cases is noted, with some individuals still adhering to strict testing and isolation protocols.
Deborah Birx on COVID-19 Summer Waves and Boosters
Dr. Deborah Birx appeared on ABC to discuss the predictable nature of COVID-19 summer waves and the need for seasonal boosters. Birx suggests that mRNA technology should be used to tailor vaccines for specific variants like BA.2.86 by January. The hosts critique her claims regarding the severity of COVID-19 compared to the flu and her dismissal of monoclonal antibodies in favor of antivirals like Remdesivir.
mRNA HIV Vaccine Trials and Platform Expansion
A listener report mentions a friend participating in an NIH study for an mRNA-based HIV vaccine. The hosts discuss the broader trend of the medical establishment moving toward the mRNA platform for all future vaccine development, regardless of the specific disease being targeted.
Dr. Rochelle Walensky, Vaccine Safety and Menstrual Cycles
CDC Director Dr. Rochelle Walensky appeared in a White House video stating there is no evidence that COVID-19 vaccines affect menstrual cycles. She asserted that over 250 million doses have been administered in the U.S. without any safety concerns, a claim that has met with skepticism regarding the transparency of adverse event reporting.
mRNA Technology, Johnson & Johnson Traditional Vaccine
The FDA is reviewing emergency use authorizations for mRNA vaccines from Pfizer and Moderna, which utilize a new genetic methodology. In contrast, the upcoming Johnson & Johnson vaccine uses a traditional attenuated virus approach and requires only a single dose. Concerns were raised regarding the lack of public information about mRNA technology compared to long-established vaccine production methods.
